| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (AbbVie) M16-191 | A Randomized, Open-Label, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib Alone In Subjects With Myelofibrosis | Leber, Dr Brian | Open to recruitment | NCT04472598 |
| (AbbVie) M19-708 / VIALE-M | Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) | Leber, Dr Brian | Open to recruitment | NCT04102020 |
| (AbbVie) M20-178 / TRANSFORM-2 | A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | Leber, Dr Brian | Open to recruitment | NCT04468984 |
| (Celgene) ACE-536-MDS-002 / COMMANDS | A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions | Leber, Dr Brian | Open to recruitment | NCT03682536 |
| (Constellation) CPI-0610-02 / MANIFEST study | A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) | Leber, Dr Brian | Open to recruitment | NCT02158858 |
| (Horizon Health Network) The M4 Study | The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Cohort Study (The M4 Study) | Mian, Dr Hira | Open to recruitment | NCT03421132 |
| (McMaster) CTTC 1901 / OZM-099 | A Randomized Pilot Trial comparing Anti-Thymocyte Globulin (ATG) with ATG plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT) | Walker, Dr Irwin | Open to recruitment | NCT04202835 |
| (Novartis) CCTL019B2302 | A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label Indication | Kouroukis, Dr Tom | Open to recruitment | NCT04094311 |
| CMRG 007 / MCRN 007 / ALGONQUIN | A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM) | Mian, Dr Hira | Open to recruitment | NCT03715478 |
| (CCTG) LY.17 | A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Fraser, Dr Graeme | Suspended/On hold | NCT02436707 |
| (Celgene) CC-97540-NHL-001 | A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC-97540, CD19-TARGETED NEX-T CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL NONHODGKIN LYMPHOMA | Foley, Dr Ronan | Suspended/On hold | NCT04231747 |
| CMRG 008 | A Phase 2 Multi-Center, Open Label Study of Isatuximab added to standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma | Mian, Dr Hira | Suspended/On hold | NCT04786028 |
Find a Trial
Contact Us